KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Payables (2016 - 2025)

Emergent BioSolutions' Payables history spans 16 years, with the latest figure at $55.6 million for Q4 2025.

  • For Q4 2025, Payables fell 8.7% year-over-year to $55.6 million; the TTM value through Dec 2025 reached $55.6 million, down 8.7%, while the annual FY2025 figure was $55.6 million, 8.7% down from the prior year.
  • Payables reached $55.6 million in Q4 2025 per EBS's latest filing, down from $57.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.1 billion in Q1 2023 to a low of $55.6 million in Q4 2025.
  • Average Payables over 5 years is $313.8 million, with a median of $163.6 million recorded in 2021.
  • Peak YoY movement for Payables: surged 673.87% in 2023, then tumbled 89.61% in 2025.
  • A 5-year view of Payables shows it stood at $160.5 million in 2021, then skyrocketed by 560.93% to $1.1 billion in 2022, then tumbled by 50.42% to $525.9 million in 2023, then crashed by 88.42% to $60.9 million in 2024, then dropped by 8.7% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Payables are $55.6 million (Q4 2025), $57.4 million (Q3 2025), and $63.7 million (Q2 2025).